| Dec 11, 2025 |
Dec 15, 2025 |
Climb Bio, Inc.
|
Director |
Buy |
20.0
|
-20,125,439
|
-85.56%
|
✗
|
$754.7K |
| Dec 8, 2025 |
Dec 10, 2025 |
Fulcrum Therapeutics, Inc.
|
10% Owner |
Sell |
15.0
|
-4,175,139
|
-40.82%
|
✗
|
$58.4M |
| Nov 20, 2025 |
Nov 24, 2025 |
Sionna Therapeutics, Inc.
|
Director |
Sell |
42.5
|
-30,316
|
-0.10%
|
✗
|
$1.2M |
| Nov 17, 2025 |
Nov 19, 2025 |
Sionna Therapeutics, Inc.
|
Director |
Sell |
33.8
|
-136,351
|
-0.23%
|
✗
|
$5.5M |
| Nov 13, 2025 |
Nov 14, 2025 |
Wave Life Sciences Ltd.
|
Director |
Buy |
47.5
|
+1,000
|
0.01%
|
✗
|
$6.7K |
| Oct 28, 2025 |
Oct 30, 2025 |
Vor Biopharma Inc.
|
Director |
Sell |
15.0
|
-400,408
|
-33.93%
|
✗
|
$10.4M |
| Oct 24, 2025 |
Oct 28, 2025 |
Sionna Therapeutics, Inc.
|
Director |
Sell |
15.0
|
-373,610
|
-1.82%
|
✗
|
$14.8M |
| Oct 23, 2025 |
Oct 27, 2025 |
Vor Biopharma Inc.
|
Director |
Sell |
16.3
|
-221,166
|
-15.78%
|
✗
|
$6.2M |
| Oct 20, 2025 |
Oct 22, 2025 |
Vor Biopharma Inc.
|
Director |
Sell |
17.5
|
-117,050
|
-2.67%
|
✗
|
$3.4M |
| Oct 15, 2025 |
Oct 17, 2025 |
Vor Biopharma Inc.
|
Director |
Sell |
15.0
|
-464,025
|
-3.24%
|
✗
|
$13.7M |
| Sep 26, 2025 |
Sep 30, 2025 |
PepGen Inc.
|
Director |
Buy |
100.0
|
+9,375,000
|
102.13%
|
✗
|
$30M |
| Sep 4, 2025 |
Sep 8, 2025 |
Mineralys Therapeutics, Inc.
|
Director |
Buy |
100.0
|
+1,176,470
|
27.49%
|
✗
|
$30M |
| Jun 26, 2025 |
Jun 30, 2025 |
Cidara Therapeutics, Inc.
|
Director |
Buy |
100.0
|
+2,272,727
|
207.97%
|
✗
|
$100M |
| Jun 12, 2025 |
Jun 16, 2025 |
Tyra Biosciences, Inc.
|
Director |
Buy |
87.5
|
+163,287
|
1.62%
|
✗
|
$1.7M |
| Jun 9, 2025 |
Jun 11, 2025 |
Tyra Biosciences, Inc.
|
Director |
Buy |
87.5
|
+186,850
|
1.89%
|
✗
|
$1.9M |
| Jun 4, 2025 |
Jun 6, 2025 |
Tyra Biosciences, Inc.
|
Director |
Buy |
100.0
|
+1,211,198
|
13.93%
|
✗
|
$11.8M |
| May 12, 2025 |
May 14, 2025 |
Werewolf Therapeutics, Inc.
|
Director |
Buy |
92.5
|
+536,426
|
9.41%
|
✗
|
$487.2K |
| Mar 13, 2025 |
Mar 17, 2025 |
Mineralys Therapeutics, Inc.
|
Director |
Buy |
100.0
|
+1,296,296
|
43.45%
|
✗
|
$17.5M |
| Mar 5, 2025 |
Mar 7, 2025 |
Janux Therapeutics, Inc.
|
Director |
Buy |
97.5
|
+824,041
|
8.84%
|
✗
|
$25.3M |
| Feb 10, 2025 |
Feb 10, 2025 |
Sionna Therapeutics, Inc.
|
Director |
Buy |
100.0
|
+1,125,000
|
13.85%
|
✗
|
$20.3M |
| Jan 30, 2025 |
Feb 3, 2025 |
89bio, Inc.
|
Director |
Buy |
100.0
|
+5,714,285
|
41.29%
|
✗
|
$50M |
| Nov 8, 2024 |
Nov 13, 2024 |
Tyra Biosciences, Inc.
|
Director |
Buy |
100.0
|
+1,220,681
|
16.33%
|
✗
|
$19.8M |
| Oct 28, 2024 |
Oct 30, 2024 |
Septerna, Inc.
|
Director |
Buy |
100.0
|
+4,170,000
|
147.57%
|
✗
|
$75.1M |
| Oct 18, 2024 |
Oct 22, 2024 |
Janux Therapeutics, Inc.
|
Director |
Buy |
100.0
|
+1,200,000
|
14.78%
|
✗
|
$53.7M |
| Sep 16, 2024 |
Sep 18, 2024 |
Bicara Therapeutics Inc.
|
Director |
Buy |
100.0
|
+1,833,000
|
35.78%
|
✗
|
$33M |
| Aug 9, 2024 |
Aug 13, 2024 |
AN2 Therapeutics, Inc.
|
10% Owner |
Sell |
17.5
|
-3,525,094
|
-63.50%
|
✗
|
$3.8M |
| Jul 22, 2024 |
Jul 24, 2024 |
Artiva Biotherapeutics, Inc.
|
Director |
Buy |
100.0
|
+8,795,020
|
459.88%
|
✗
|
$104.7M |
| Jun 27, 2024 |
Jul 1, 2024 |
Climb Bio, Inc.
|
Director |
Buy |
100.0
|
+18,268,418
|
76.18%
|
✗
|
$50M |
| Jun 17, 2024 |
Jun 20, 2024 |
Jade Biosciences, Inc.
|
Director |
Buy |
100.0
|
+928,110
|
13.32%
|
✗
|
$1.5M |
| Apr 2, 2024 |
Apr 4, 2024 |
Boundless Bio, Inc.
|
10% Owner |
Buy |
100.0
|
+312,500
|
16.73%
|
✗
|
$5M |
| Mar 27, 2024 |
Mar 29, 2024 |
Nkarta, Inc.
|
Director |
Buy |
100.0
|
+3,000,000
|
42.55%
|
✗
|
$30M |
| Mar 25, 2024 |
Mar 27, 2024 |
ARS Pharmaceuticals, Inc.
|
Director |
Buy |
100.0
|
+1,401,299
|
16.38%
|
✗
|
$13.3M |
| Mar 21, 2024 |
Mar 25, 2024 |
LENZ Therapeutics, Inc.
|
Director |
Buy |
100.0
|
+4,243,794
|
140.71%
|
✗
|
$15M |
| Mar 4, 2024 |
Mar 6, 2024 |
89bio, Inc.
|
Director |
Buy |
100.0
|
+1,350,000
|
12.18%
|
✗
|
$20.7M |
| Feb 9, 2024 |
Feb 13, 2024 |
PepGen Inc.
|
Director |
Buy |
100.0
|
+2,557,593
|
38.62%
|
✗
|
$27.2M |
| Dec 11, 2023 |
Jan 17, 2024 |
Wave Life Sciences Ltd.
|
Director |
Buy |
96.3
|
+1,000,000
|
5.81%
|
✗
|
$5M |
| Jan 11, 2024 |
Jan 12, 2024 |
Solid Biosciences Inc.
|
Director |
Buy |
100.0
|
+904,160
|
27.50%
|
✗
|
$5M |
| Dec 11, 2023 |
Dec 13, 2023 |
Wave Life Sciences Ltd.
|
Director |
Buy |
96.3
|
+1,000,000
|
5.49%
|
✗
|
$5M |
| Sep 21, 2023 |
Sep 25, 2023 |
ARS Pharmaceuticals, Inc.
|
Director |
Buy |
100.0
|
+2,700,000
|
46.10%
|
✗
|
$8.2M |
| Aug 29, 2023 |
Aug 31, 2023 |
ARS Pharmaceuticals, Inc.
|
Director |
Buy |
100.0
|
+3,750,000
|
178.00%
|
✗
|
$23.3M |
| Aug 18, 2023 |
Aug 22, 2023 |
AN2 Therapeutics, Inc.
|
10% Owner |
Buy |
100.0
|
+1,777,778
|
52.94%
|
✗
|
$16M |
| Jul 21, 2023 |
Jul 25, 2023 |
Acumen Pharmaceuticals, Inc.
|
Director |
Buy |
100.0
|
+5,161,290
|
65.48%
|
✗
|
$40M |
| Jul 19, 2023 |
Jul 21, 2023 |
Janux Therapeutics, Inc.
|
Director |
Buy |
96.3
|
+495,008
|
6.49%
|
✗
|
$6.2M |
| Jul 5, 2023 |
Jul 7, 2023 |
Black Diamond Therapeutics, Inc.
|
Director |
Buy |
100.0
|
+935,850
|
41.08%
|
✗
|
$4.7M |
| Mar 24, 2023 |
Mar 30, 2023 |
89bio, Inc.
|
Director |
Buy |
100.0
|
+2,461,538
|
28.56%
|
✗
|
$40M |
| Feb 14, 2023 |
Feb 16, 2023 |
Mineralys Therapeutics, Inc.
|
Director |
Buy |
100.0
|
+1,250,000
|
64.82%
|
✗
|
$20M |
| Jan 20, 2023 |
Jan 24, 2023 |
Fulcrum Therapeutics, Inc.
|
10% Owner |
Buy |
100.0
|
+1,923,076
|
19.85%
|
✗
|
$25M |
| Jan 6, 2023 |
Jan 10, 2023 |
Werewolf Therapeutics, Inc.
|
Director |
Buy |
100.0
|
+1,853,000
|
48.15%
|
✗
|
$4.1M |
| Jan 4, 2023 |
Jan 6, 2023 |
Fulcrum Therapeutics, Inc.
|
10% Owner |
Buy |
87.5
|
+180,703
|
1.90%
|
✗
|
$1.3M |
| Jan 3, 2023 |
Jan 5, 2023 |
Enliven Therapeutics, Inc.
|
10% Owner |
Buy |
100.0
|
+629,297
|
19.36%
|
✗
|
$2.5M |
| Dec 27, 2022 |
Dec 29, 2022 |
Fulcrum Therapeutics, Inc.
|
10% Owner |
Buy |
48.8
|
+4,089
|
0.04%
|
✗
|
$24.5K |
| Dec 19, 2022 |
Dec 21, 2022 |
Fulcrum Therapeutics, Inc.
|
10% Owner |
Buy |
85.0
|
+98,787
|
1.05%
|
✗
|
$582.8K |
| Dec 14, 2022 |
Dec 16, 2022 |
Fulcrum Therapeutics, Inc.
|
10% Owner |
Buy |
100.0
|
+2,403,049
|
34.33%
|
✗
|
$13.1M |
| Dec 8, 2022 |
Dec 12, 2022 |
Enliven Therapeutics, Inc.
|
10% Owner |
Buy |
72.5
|
+29,899
|
0.93%
|
✗
|
$115.6K |
| Nov 17, 2022 |
Nov 21, 2022 |
Acrivon Therapeutics, Inc.
|
Director |
Buy |
100.0
|
+3,389,500
|
340.75%
|
✗
|
$42.4M |
| Oct 20, 2022 |
Oct 24, 2022 |
Enliven Therapeutics, Inc.
|
10% Owner |
Buy |
90.0
|
+85,902
|
2.74%
|
✗
|
$336.8K |
| Oct 18, 2022 |
Oct 20, 2022 |
89bio, Inc.
|
Director |
Buy |
100.0
|
+1,172,741
|
15.07%
|
✗
|
$9M |
| Oct 17, 2022 |
Oct 19, 2022 |
Enliven Therapeutics, Inc.
|
10% Owner |
Buy |
100.0
|
+506,197
|
19.26%
|
✗
|
$1.9M |
| Aug 3, 2022 |
Aug 5, 2022 |
AN2 Therapeutics, Inc.
|
10% Owner |
Buy |
48.8
|
+1,909
|
0.03%
|
✗
|
$14.3K |
| Jul 26, 2022 |
Jul 28, 2022 |
AN2 Therapeutics, Inc.
|
10% Owner |
Buy |
72.5
|
+23,219
|
0.62%
|
✗
|
$180.7K |
| Jul 1, 2022 |
Jul 6, 2022 |
89bio, Inc.
|
Director |
Buy |
100.0
|
+2,816,900
|
56.73%
|
✗
|
$10M |
| Jun 21, 2022 |
Jun 23, 2022 |
AN2 Therapeutics, Inc.
|
10% Owner |
Buy |
47.5
|
+302
|
0.01%
|
✗
|
$2.4K |
| Jun 16, 2022 |
Jun 21, 2022 |
Wave Life Sciences Ltd.
|
Director |
Buy |
100.0
|
+9,480,052
|
122.77%
|
✗
|
$20.4M |
| Jun 13, 2022 |
Jun 15, 2022 |
AN2 Therapeutics, Inc.
|
10% Owner |
Buy |
85.0
|
+81,424
|
2.22%
|
✗
|
$647.4K |
| May 26, 2022 |
May 26, 2022 |
KALA BIO, Inc.
|
10% Owner |
Sell |
20.0
|
-1,005,686
|
-12.50%
|
✗
|
$365.7K |
| May 23, 2022 |
May 25, 2022 |
KALA BIO, Inc.
|
10% Owner |
Sell |
17.5
|
-2,829,314
|
-26.02%
|
✗
|
$1.5M |
| May 10, 2022 |
May 12, 2022 |
PepGen Inc.
|
Director |
Buy |
100.0
|
+3,229,200
|
68.78%
|
✗
|
$38.8M |
| Apr 26, 2022 |
Apr 28, 2022 |
Nkarta, Inc.
|
Director |
Buy |
100.0
|
+2,200,000
|
39.25%
|
✗
|
$33M |
| Mar 29, 2022 |
Mar 31, 2022 |
AN2 Therapeutics, Inc.
|
10% Owner |
Buy |
100.0
|
+1,666,666
|
83.33%
|
✗
|
$25M |
| Mar 14, 2022 |
Mar 16, 2022 |
Cytek Biosciences, Inc.
|
Director |
Buy |
93.8
|
+583,870
|
4.56%
|
✓
|
$7.2M |
| Mar 9, 2022 |
Mar 11, 2022 |
Cytek Biosciences, Inc.
|
Director |
Buy |
96.3
|
+634,638
|
5.22%
|
✓
|
$8.2M |
| Mar 4, 2022 |
Mar 8, 2022 |
Cytek Biosciences, Inc.
|
Director |
Buy |
96.3
|
+647,264
|
5.62%
|
✓
|
$8.2M |
| Feb 28, 2022 |
Mar 2, 2022 |
Cytek Biosciences, Inc.
|
Director |
Buy |
93.8
|
+441,865
|
3.99%
|
✓
|
$5.7M |
| Feb 23, 2022 |
Feb 25, 2022 |
Cytek Biosciences, Inc.
|
Director |
Buy |
93.8
|
+420,380
|
3.95%
|
✓
|
$5.6M |
| Feb 17, 2022 |
Feb 22, 2022 |
Cytek Biosciences, Inc.
|
Director |
Buy |
96.3
|
+547,380
|
5.42%
|
✓
|
$7.7M |
| Feb 14, 2022 |
Feb 16, 2022 |
Cytek Biosciences, Inc.
|
Director |
Buy |
96.3
|
+498,629
|
5.19%
|
✓
|
$7.4M |
| Sep 17, 2021 |
Sep 17, 2021 |
Tyra Biosciences, Inc.
|
Director |
Buy |
100.0
|
+1,250,000
|
30.89%
|
✗
|
$20M |
| Aug 12, 2021 |
Aug 16, 2021 |
Climb Bio, Inc.
|
Director |
Buy |
100.0
|
+3,200,000
|
40.59%
|
✗
|
$40M |
| Jul 27, 2021 |
Jul 29, 2021 |
Cytek Biosciences, Inc.
|
Director |
Buy |
100.0
|
+2,950,000
|
47.97%
|
✗
|
$50.2M |
| Jul 6, 2021 |
Jul 8, 2021 |
Acumen Pharmaceuticals, Inc.
|
Director |
Buy |
100.0
|
+1,875,000
|
25.66%
|
✗
|
$30M |
| Jul 2, 2021 |
Jul 6, 2021 |
Jade Biosciences, Inc.
|
Director |
Buy |
100.0
|
+2,785,714
|
66.65%
|
✗
|
$39M |
| Jun 15, 2021 |
Jun 16, 2021 |
Janux Therapeutics, Inc.
|
Director |
Buy |
100.0
|
+2,941,176
|
51.33%
|
✗
|
$50M |
| Jun 14, 2021 |
Jun 16, 2021 |
Werewolf Therapeutics, Inc.
|
Director |
Buy |
95.0
|
+323,298
|
8.15%
|
✗
|
$4.1M |
| Jun 2, 2021 |
Jun 4, 2021 |
89bio, Inc.
|
Director |
Buy |
67.5
|
+22,138
|
0.45%
|
✗
|
$415.5K |
| May 26, 2021 |
May 28, 2021 |
89bio, Inc.
|
Director |
Buy |
92.5
|
+207,417
|
4.38%
|
✗
|
$3.9M |
| May 4, 2021 |
May 6, 2021 |
Werewolf Therapeutics, Inc.
|
Director |
Buy |
100.0
|
+1,715,000
|
76.10%
|
✗
|
$27.4M |
| Apr 1, 2021 |
Apr 5, 2021 |
Vor Biopharma Inc.
|
10% Owner |
Buy |
100.0
|
+998,382
|
12.03%
|
✗
|
$43M |
| Apr 1, 2021 |
Apr 5, 2021 |
Wave Life Sciences Ltd.
|
10% Owner |
Buy |
100.0
|
+970,025
|
14.25%
|
✗
|
$5.4M |
| Apr 1, 2021 |
Apr 5, 2021 |
Solid Biosciences Inc.
|
Director |
Buy |
100.0
|
+1,451,306
|
13.29%
|
✗
|
$8M |
| Apr 1, 2021 |
Apr 5, 2021 |
Nkarta, Inc.
|
10% Owner |
Buy |
100.0
|
+568,033
|
13.26%
|
✗
|
$18.7M |
| Apr 1, 2021 |
Apr 5, 2021 |
KALA BIO, Inc.
|
10% Owner |
Buy |
100.0
|
+1,687,709
|
18.37%
|
✗
|
$11.4M |
| Apr 1, 2021 |
Apr 5, 2021 |
89bio, Inc.
|
10% Owner |
Buy |
100.0
|
+628,277
|
16.65%
|
✗
|
$14.9M |
| Mar 19, 2021 |
Mar 23, 2021 |
Solid Biosciences Inc.
|
Director |
Buy |
100.0
|
+2,206,685
|
25.34%
|
✗
|
$12.7M |
| Mar 12, 2021 |
Mar 16, 2021 |
scPharmaceuticals Inc.
|
10% Owner |
Sell |
17.5
|
-150,057
|
-5.21%
|
✗
|
$1.1M |
| Mar 11, 2021 |
Mar 15, 2021 |
Phathom Pharmaceuticals, Inc.
|
10% Owner |
Sell |
15.0
|
-710,000
|
-18.56%
|
✗
|
$31.1M |
| Feb 9, 2021 |
Feb 9, 2021 |
Vor Biopharma Inc.
|
Director |
Buy |
100.0
|
+2,979,566
|
41.71%
|
✗
|
$53.6M |
| Dec 2, 2020 |
Dec 4, 2020 |
RHYTHM PHARMACEUTICALS, INC.
|
Other |
Sell |
16.3
|
-238,543
|
-5.19%
|
✗
|
$7M |
| Oct 7, 2020 |
Oct 9, 2020 |
Vaxcyte, Inc.
|
10% Owner |
Sell |
15.0
|
-266,258
|
-5.05%
|
✗
|
$13.5M |
| Sep 29, 2020 |
Oct 1, 2020 |
Vaxcyte, Inc.
|
10% Owner |
Sell |
15.0
|
-221,330
|
-2.03%
|
✗
|
$11.2M |
| Sep 17, 2020 |
Sep 21, 2020 |
89bio, Inc.
|
Director |
Buy |
100.0
|
+1,300,000
|
37.83%
|
✗
|
$36.4M |